Live IPO - Mediland Pharm Ltd.

mediland pharm.jpg

Mediland Pharm Ltd (ASX: MPH) was founded as a Sydney based family business in 2002 and has grown to become a market leading retailer servicing the Chinese inbound tourism sector in Australia. With three strategically located retail outlets in Sydney, Melbourne and Surfers Paradise, the Company’s retail experience and merchandising strategies are designed to capture a significant share of the spending of the various tour groups.

By partnering with major travel agents and wholesale tour operators who are all Chinese Government certified under the Approved Destination Status (ADS) scheme, Mediland Pharm has grown strongly over the years, consistent with the growth of inbound tourist numbers from China and increasing level of expenditure by Chinese tourists.

  • Pay by: 11 February 19

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus


Live IPO - HeraMED Limited.

hera med.png

HeraMED (ASX:HMD) was incorporated in 2011 in Israel as a technology start-up developing innovative, connected pregnancy monitoring solutions.Its first commercial product, HeraBEAT™ is a medical-grade, clinically validated fetal heart rate monitor mainly for home use.

Today, fetal heart monitoring is a standard part of every pregnancy check-up, but current technologies are expensive, bulky, limited and designed for professional use only. The result is that pregnancy monitoring almost always requires a clinical setting, a nurse or doctor to conduct the measurement and the careful attention of a trained obstetrician-gynaecologist for a subjective, time-consuming, visual interpretation of FHR pattern recognition and assessment.

HeraMED’s aim is to become a world leader in innovative, accessible, technology-driven products which change the way practitioners and expectant mothers approach and monitor the miracle of pregnancy.

  • Pay by: 2 November 18

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $5,000

  • Prospectus